MX2007009070A - (spm 927) para terapia supletoria de esquizofrenia. - Google Patents

(spm 927) para terapia supletoria de esquizofrenia.

Info

Publication number
MX2007009070A
MX2007009070A MX2007009070A MX2007009070A MX2007009070A MX 2007009070 A MX2007009070 A MX 2007009070A MX 2007009070 A MX2007009070 A MX 2007009070A MX 2007009070 A MX2007009070 A MX 2007009070A MX 2007009070 A MX2007009070 A MX 2007009070A
Authority
MX
Mexico
Prior art keywords
therapy
add
schizophrenia
spm
antipsychotics
Prior art date
Application number
MX2007009070A
Other languages
English (en)
Spanish (es)
Inventor
Thomas Stohr
Original Assignee
Sanol Arznei Schwarz Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP05001843A external-priority patent/EP1688137A1/fr
Application filed by Sanol Arznei Schwarz Gmbh filed Critical Sanol Arznei Schwarz Gmbh
Publication of MX2007009070A publication Critical patent/MX2007009070A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
MX2007009070A 2005-01-28 2006-01-27 (spm 927) para terapia supletoria de esquizofrenia. MX2007009070A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US64741005P 2005-01-28 2005-01-28
EP05001843A EP1688137A1 (fr) 2005-01-28 2005-01-28 SPM 927 pour la thérapie adjuvante de la schizophrenie
PCT/EP2006/000722 WO2006079547A2 (fr) 2005-01-28 2006-01-27 Lacosamide pour traitement d'appoint

Publications (1)

Publication Number Publication Date
MX2007009070A true MX2007009070A (es) 2007-09-12

Family

ID=36636204

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007009070A MX2007009070A (es) 2005-01-28 2006-01-27 (spm 927) para terapia supletoria de esquizofrenia.

Country Status (12)

Country Link
EP (1) EP1841417A2 (fr)
JP (1) JP2008528532A (fr)
KR (1) KR20070096058A (fr)
AR (1) AR057643A1 (fr)
AU (1) AU2006208630B2 (fr)
BR (1) BRPI0607043A2 (fr)
CA (1) CA2595330A1 (fr)
EA (1) EA015566B1 (fr)
IL (1) IL183973A0 (fr)
MX (1) MX2007009070A (fr)
NO (1) NO20074361L (fr)
WO (1) WO2006079547A2 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1873527A1 (fr) 2006-06-30 2008-01-02 Schwarz Pharma Ag Procédé d'identification des modulateurs CRMP
EP2037965B1 (fr) * 2006-06-15 2017-08-30 UCB Pharma GmbH Composition pharmaceutique ayant un effet anticonvulsivant synergique
EP1920780A1 (fr) * 2006-10-12 2008-05-14 Schwarz Pharma Ag Composés peptidiques pour le traitement des maladies liées à l'hyperexcitabilité
CN101466390B (zh) 2006-06-15 2014-03-12 优时比制药有限公司 用于治疗难治性癫痫持续状态的肽类化合物
WO2009053070A1 (fr) 2007-10-23 2009-04-30 Schwarz Pharma Ag Composés pour le traitement de conditions de démyélinisation
US20100151021A1 (en) * 2008-12-16 2010-06-17 Venkatesh Gopi M Compositions Comprising Melperone
EP2468261A1 (fr) 2010-12-02 2012-06-27 UCB Pharma GmbH Formulation de lacosamide
AU2011335415B2 (en) 2010-12-02 2016-05-19 Ucb Pharma Gmbh Once daily formulation of lacosamide
BR112019012573A2 (pt) 2016-12-20 2019-11-19 Lts Lohmann Therapie Systeme Ag sistema terapêutico transdérmico que contém asenapina e polissiloxano ou poli-isobutileno
EP3338768B1 (fr) 2016-12-20 2019-10-30 LTS Lohmann Therapie-Systeme AG Système thérapeutique transdermique contenant de l'asénapine
WO2019002204A1 (fr) 2017-06-26 2019-01-03 Lts Lohmann Therapie-Systeme Ag Système thérapeutique transdermique contenant de l'asénapine et un polymère hybride acrylique de type silicone
WO2019113079A1 (fr) 2017-12-05 2019-06-13 Sunovion Pharmaceuticals Inc. Mélanges non racémiques et leurs utilisations
WO2019113084A1 (fr) 2017-12-05 2019-06-13 Sunovion Pharmaceuticals Inc. Formes cristallines et leurs procédés de production
BR112020026099A2 (pt) 2018-06-20 2021-03-23 Lts Lohmann Therapie-Systeme Ag sistema terapêutico transdérmico que contém asenapina
KR20220018004A (ko) 2019-06-04 2022-02-14 선오비온 파마슈티컬스 인코포레이티드 조절 방출 제형 및 이의 용도
US11278634B1 (en) 2021-02-12 2022-03-22 Extrovis Ag Stable parenteral composition of lacosamide

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5378729A (en) * 1985-02-15 1995-01-03 Research Corporation Technologies, Inc. Amino acid derivative anticonvulsant
US5773475A (en) 1997-03-17 1998-06-30 Research Corporation Technologies, Inc. Anticonvulsant enantiomeric amino acid derivatives
ES2262567T3 (es) 2001-03-20 2006-12-01 Schwarz Pharma Ag Nuevo uso de una clase peptidica de compuesto para tratamiento del dolor inflamatorio no neuropatico.
ES2185606T3 (es) 2001-03-21 2003-05-01 Sanol Arznei Schwarz Gmbh Nuevo uso de una clase de compuestos peptidicos para tratamiento de la alodinia u otros tipos diferentes de dolor cronico o fantasma.

Also Published As

Publication number Publication date
WO2006079547A3 (fr) 2006-09-21
EP1841417A2 (fr) 2007-10-10
JP2008528532A (ja) 2008-07-31
EA015566B1 (ru) 2011-10-31
IL183973A0 (en) 2008-12-29
WO2006079547A2 (fr) 2006-08-03
AU2006208630B2 (en) 2011-09-29
AU2006208630A1 (en) 2006-08-03
NO20074361L (no) 2007-10-26
EA200701594A1 (ru) 2008-02-28
KR20070096058A (ko) 2007-10-01
AR057643A1 (es) 2007-12-12
CA2595330A1 (fr) 2006-08-03
BRPI0607043A2 (pt) 2009-08-04

Similar Documents

Publication Publication Date Title
MX2007009070A (es) (spm 927) para terapia supletoria de esquizofrenia.
TW200637538A (en) Lacosamide for add-on-therapy
GB0225474D0 (en) Therapeutic agents
GB0223038D0 (en) Therapeutic compounds
MY147247A (en) Organic compounds and their uses
HK1121440A1 (en) Biphenyl derivatives and their use in treating hepatitis c
HK1111083A1 (en) 3,11b cis dihydrotetrabanezine for the treatment of schizophrenia and other psychoses
ZA200709535B (en) Methods and compositions for the treatment of CNS-related conditions
GB0108592D0 (en) Therapeutic agents
GB0223040D0 (en) Therapeutic compounds
PL1919466T3 (pl) Formulacje do leczenia nieprawidłowości lipoproteinowych obejmujące statynę i pochodną metylonikotynoamidu
TW200800976A (en) New compounds for the treatment of neurological, psychiatric or pain disorders
MX2007011023A (es) 2-(4-oxo-4h-quinazolin-3-il) acetamidas y su uso como antagonistas de vasopresin v3.
MX2007007409A (es) Derivados de rapamicina y los usos de los mismos en el tratamiento de trastornos neurologicos.
EP1673078A4 (fr) Inhibiteurs de type benzylether et benzylamino de beta-secretase pour le traitement de la maladie d'alzheimer
UA94580C2 (ru) Аналог 39-дезметоксирапамицина, способный преодолевать гематоэнцефалический барьер, для лечения патологического состояния, вызванного нейрогенным повреждением или заболеванием
TNSN06071A1 (en) Use of modified cyclosporins for the treatment of hcv disorders
NZ595571A (en) Pyrazole compounds and uses thereof
HK1166465A1 (en) 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position as parp inhibitors for use in treating cancer
UY29112A1 (es) Derivados de pirazol condensado, su preparacion y su aplicacion terapeutica
GB2442915B (en) Perylenequinone derivatives and uses thereof
BRPI0513317A (pt) ciclosporinas para tratar doença de alzheimer
TW200716091A (en) New therapeutic combinations for the treatment or prevention of psychotic disorders
BRPI0510947A (pt) tratamento de doença respiratória
MY162640A (en) Thioninium compounds and their use

Legal Events

Date Code Title Description
HC Change of company name or juridical status
FG Grant or registration